Finch Therapeutics Group, Inc. (FNCH)
USD 12.74
(-0.08%)
USD 12.74
(-0.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -32.48 Million USD | 56.49% |
| 2022 | -82.68 Million USD | -24.44% |
| 2021 | -57.68 Million USD | -55.27% |
| 2020 | -38.64 Million USD | -88.27% |
| 2019 | -20.66 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -6.06 Million USD | -18.43% |
| 2024 Q1 | -5.12 Million USD | -10.44% |
| 2023 Q3 | -3.78 Million USD | 61.13% |
| 2023 FY | - USD | 56.49% |
| 2023 Q4 | -4.63 Million USD | -22.64% |
| 2023 Q2 | -9.72 Million USD | -131.2% |
| 2023 Q1 | 31.17 Million USD | 214.35% |
| 2022 Q2 | -19.45 Million USD | 16.32% |
| 2022 Q1 | -23.24 Million USD | -21.97% |
| 2022 FY | - USD | -24.44% |
| 2022 Q4 | -27.26 Million USD | -4658.46% |
| 2022 Q3 | -573 Thousand USD | 97.05% |
| 2021 FY | - USD | -55.27% |
| 2021 Q4 | -19.06 Million USD | -105.08% |
| 2021 Q3 | -9.29 Million USD | 49.0% |
| 2021 Q1 | -13.97 Million USD | -8.3% |
| 2021 Q2 | -18.22 Million USD | -30.43% |
| 2020 FY | - USD | -88.27% |
| 2020 Q4 | -12.9 Million USD | -30.62% |
| 2020 Q3 | -9.87 Million USD | -21.17% |
| 2020 Q2 | -8.15 Million USD | -5.84% |
| 2020 Q1 | -7.7 Million USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -7161.923% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -10.086% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 71.521% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -106.091% |
| Better Therapeutics, Inc. | -38.26 Million USD | 15.106% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 15.113% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -81.6% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 3.709% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 2.67% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 69.456% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -3455.88% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 30.433% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -471.489% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -99.261% |
| Molecular Templates, Inc. | 1.43 Million USD | 2371.469% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -134.103% |
| NexImmune, Inc. | -28.16 Million USD | -15.317% |
| Orgenesis Inc. | -60.71 Million USD | 46.504% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 36.675% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -44143.762% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -101.186% |
| Scopus BioPharma Inc. | -11.71 Million USD | -177.312% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 93.984% |
| Statera Biopharma, Inc. | 38.93 Million USD | 183.426% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -371.848% |
| Trevena, Inc. | -35.28 Million USD | 7.952% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -57850.795% |
| Vaccinex, Inc. | -19.74 Million USD | -64.482% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -3002.453% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 30.686% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -347.225% |